Export

EN
FR
Atoltivimab + maftivimab + odesivimab
Essential medicine status
General description

Medicine type
Biological agent
EML status history
First added in 2023 (TRS 1049) for Ebola virus disease
Recommendations
Section
Medicines for Ebola virus disease
  • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial